New immune cell therapy takes on Hard-to-Treat myeloma

NCT ID NCT03710421

Terminated Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial tests a new immune cell therapy called CS1-CAR T cells for people with multiple myeloma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack myeloma cells, and infusing them back after chemotherapy. The main goals are to find the safest dose and to watch for side effects in 30 adult participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS1-CAR T cells (engineered immune cells)
What this could lead to: If successful, this could lead to a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and prolonged low white blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT PLASMA CELL MYELOMA REFRACTORY PLASMA CELL MYELOMA

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.